170 related articles for article (PubMed ID: 35780549)
1. Orally administered covalently-assembled antioxidative peptide nanoparticles for inflammatory bowel disease therapy.
Ma X; Gong H; Liu Y; Liu Y; Ogino K; Xing R; Yan X
J Colloid Interface Sci; 2022 Nov; 626():156-166. PubMed ID: 35780549
[TBL] [Abstract][Full Text] [Related]
2. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy.
Xu C; Chen S; Chen C; Ming Y; Du J; Mu J; Luo F; Huang D; Wang N; Lin Z; Weng Z
Int J Pharm; 2022 Jul; 623():121884. PubMed ID: 35661797
[TBL] [Abstract][Full Text] [Related]
3. Oral Administration of Therapeutic Enzyme Capsule for the Management of Inflammatory Bowel Disease.
Liang X; Wen K; Chen Y; Fang G; Yang S; Li Q
Int J Nanomedicine; 2022; 17():4843-4860. PubMed ID: 36262191
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles Derived from the Natural Antioxidant Rosmarinic Acid Ameliorate Acute Inflammatory Bowel Disease.
Chung CH; Jung W; Keum H; Kim TW; Jon S
ACS Nano; 2020 Jun; 14(6):6887-6896. PubMed ID: 32449857
[TBL] [Abstract][Full Text] [Related]
5. Orally administered titanium carbide nanosheets as anti-inflammatory therapy for colitis.
Hou L; Gong F; Liu B; Yang X; Chen L; Li G; Gong Y; Liang C; Yang N; Shen X; Liu Z; Cheng L
Theranostics; 2022; 12(8):3834-3846. PubMed ID: 35664066
[No Abstract] [Full Text] [Related]
6. Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis.
Min DK; Kim YE; Kim MK; Choi SW; Park N; Kim J
ACS Nano; 2023 Dec; 17(23):24404-24416. PubMed ID: 38039189
[TBL] [Abstract][Full Text] [Related]
7. Readily Available Oral Prebiotic Protein Reactive Oxygen Species Nanoscavengers for Synergistic Therapy of Inflammation and Fibrosis in Inflammatory Bowel Disease.
Yu Y; Yang D; Lin B; Zhu L; Li C; Li X
ACS Nano; 2024 May; 18(21):13583-13598. PubMed ID: 38740518
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.
Seoudi SS; Allam EA; El-Kamel AH; Elkafrawy H; El-Moslemany RM
Drug Deliv Transl Res; 2023 Nov; 13(11):2930-2947. PubMed ID: 37184747
[TBL] [Abstract][Full Text] [Related]
9. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
10. Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.
Laroui H; Viennois E; Xiao B; Canup BS; Geem D; Denning TL; Merlin D
J Control Release; 2014 Jul; 186():41-53. PubMed ID: 24810114
[TBL] [Abstract][Full Text] [Related]
11. Orally Administered Silicon Hydrogen Nanomaterials as Target Therapy to Treat Intestinal Diseases.
Wei K; Gong F; Wu J; Tang W; Liao F; Han Z; Pei Z; Lei H; Wang L; Shao M; Liu Z; Cheng L
ACS Nano; 2023 Nov; 17(21):21539-21552. PubMed ID: 37843009
[TBL] [Abstract][Full Text] [Related]
12. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease.
Zhang C; Zeng F; Fan Z; He Z; Tai L; Peng Q; Zhang Y; Chao Z; Jiang W; Jia L; Han L
Acta Biomater; 2023 Oct; 169():422-433. PubMed ID: 37597682
[TBL] [Abstract][Full Text] [Related]
13. SHARP hydrogel for the treatment of inflammatory bowel disease.
Poláková L; Raus V; Cuchalová L; Poręba R; Hrubý M; Kučka J; Větvička D; Trhlíková O; Sedláková Z
Int J Pharm; 2022 Feb; 613():121392. PubMed ID: 34933083
[TBL] [Abstract][Full Text] [Related]
14. Capsulated Cellular Nanosponges for the Treatment of Experimental Inflammatory Bowel Disease.
Duan Y; Zhang E; Fang RH; Gao W; Zhang L
ACS Nano; 2023 Aug; 17(16):15893-15904. PubMed ID: 37565604
[TBL] [Abstract][Full Text] [Related]
15. Construction of pH-Dependent Nanozymes with Oxygen Vacancies as the High-Efficient Reactive Oxygen Species Scavenger for Oral-Administrated Anti-Inflammatory Therapy.
Zhao N; Yang FE; Zhao CY; Lv SW; Wang J; Liu JM; Wang S
Adv Healthc Mater; 2021 Dec; 10(23):e2101618. PubMed ID: 34569192
[TBL] [Abstract][Full Text] [Related]
16. Peanut shell extract inhibits the development of dextran sulfate sodium (DSS)-induced colitis.
Lee AS; Lee KM; Lee JA; Choi I
Int Immunopharmacol; 2019 May; 70():235-240. PubMed ID: 30851703
[TBL] [Abstract][Full Text] [Related]
17. Inflammation-targeting polyamine nanomedicines for the treatment of ulcerative colitis.
Nishiguchi A; Taguchi T
J Mater Chem B; 2023 May; 11(18):4005-4013. PubMed ID: 37039159
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.
Jayawardena D; Anbazhagan AN; Guzman G; Dudeja PK; Onyuksel H
Mol Pharm; 2017 Nov; 14(11):3698-3708. PubMed ID: 28991483
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease.
Shi C; Dawulieti J; Shi F; Yang C; Qin Q; Shi T; Wang L; Hu H; Sun M; Ren L; Chen F; Zhao Y; Liu F; Li M; Mu L; Liu D; Shao D; Leong KW; She J
Sci Adv; 2022 Jan; 8(4):eabj2372. PubMed ID: 35089791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
